You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.
Noridian is also developing a generic policy for donor-derived cfDNA tests that will include several commercially available tests, Natera said.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.
The company has added three recently issued patents to the suit, filed Jan. 27, all covering methods for amplifying and sequencing nucleic acids.
The notes will be sold at an initial effective conversion price of about $38.79 per share, approximately a 30 percent premium to Monday's $29.84 per share closing price.
The company is withdrawing its previous financial guidance for 2020, saying that it cannot predict the extent or duration of the impact of the COVID-19 pandemic.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.